All In Biotech

NDA 212194 · Alnylam Pharms INC

Givlaari

Givosiran Sodium · Subcutaneous

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Nov 20, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

1 Phase 3, 0 recruiting

FAERS reports

1,559

1,173 serious, 51 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 10, 2025.

GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP). GIVLAARI is an aminolevulinate synthase 1-directed small interfering RNA indicated for the treatment of adults with acute hepatic porphyria (AHP). ( 1 )

Mechanism: Givosiran is a double-stranded small interfering RNA that causes degradation of aminolevulinate synthase 1 ( ALAS1 ) mRNA in hepatocytes through RNA interference, reducing the elevated levels of liver ALAS1 mRNA. This leads to reduced circulating levels of neurotoxic intermediates aminolevulinic acid (ALA) and porphobilinogen (PBG), factors associated with attacks and other disease manifestations of AHP.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 20, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • GIVLAARI · GIVOSIRAN SODIUM EQ 189MG BASE/ML (EQ 189MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Givosiran" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • porphyria acute495
  • hospitalisation182
  • intentional dose omission119
  • nausea118
  • product dose omission issue117
  • fatigue103
  • therapy interrupted103
  • pain92
  • malaise74
  • abdominal pain73
  • vomiting67
  • ill-defined disorder64

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202075
2021135
2022224
2023267
2024310
2025290
2026258

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Givlaari (Givosiran Sodium)

2024 spending

$20.9M

Beneficiaries

40

341 claims

Per beneficiary

$523,010

$41,591.25 per unit

View as table
YearSpending
2020$3,962,651
2021$8,050,650
2022$11,278,250
2023$14,748,145
2024$20,920,401

Part B: Givlaari (Givosiran Sodium) · HCPCS J0223

2024 spending

$16.0M

Beneficiaries

43

363 claims

Per beneficiary

$372,177

2024 ASP limit $112.13 per unit

View as table
YearSpending
2020$3,953,269
2021$10,731,532
2022$14,866,284
2023$16,461,149
2024$16,003,608

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 12 on PubMed

Sponsor: Alnylam Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.